Last $0.71 USD
Change Today -0.0005 / -0.07%
Volume 176.9K
AVEO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 4:30 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

aveo pharmaceuticals inc (AVEO) Snapshot

Open
$0.72
Previous Close
$0.71
Day High
$0.72
Day Low
$0.69
52 Week High
01/17/14 - $2.07
52 Week Low
12/9/14 - $0.61
Market Cap
37.1M
Average Volume 10 Days
446.1K
EPS TTM
$-0.85
Shares Outstanding
52.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AVEO PHARMACEUTICALS INC (AVEO)

aveo pharmaceuticals inc (AVEO) Related Businessweek News

No Related Businessweek News Found

aveo pharmaceuticals inc (AVEO) Details

AVEO Pharmaceuticals, Inc., doing business as AVEO Oncology, a biopharmaceutical company, is engaged in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform. Its therapeutic candidates under development program include AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase 1 dose escalation study; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which is in Phase 2 trial; Tivozanib, an investigational tyrosine kinase inhibitor of various vascular endothelial growth factor receptors; and AV-380 Program, a program focusing on cachexia, a serious and common complication of advanced cancer, as well as a range of chronic diseases that is characterized by unintentional weight loss, progressive muscle wasting, and a loss of appetite. AVEO Pharmaceuticals, Inc. has strategic partnerships with St. Vincent’s Hospital Sydney Limited; Kyowa Hakko Kirin; Biogen Idec, Inc.; OSI Pharmaceuticals, Inc.; Centocor Ortho Biotech Inc.; and Merck & Co., Inc. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

71 Employees
Last Reported Date: 03/13/14
Founded in 2001

aveo pharmaceuticals inc (AVEO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $567.9K
Chief Scientific Officer
Total Annual Compensation: $334.5K
Compensation as of Fiscal Year 2013.

aveo pharmaceuticals inc (AVEO) Key Developments

AVEO Oncology Signs Research and Exclusive Option Agreement with Ophthotech

AVEO Oncology signed a research and exclusive option agreement with Ophthotech, a company developing Novel Therapies for Age-Related Macular Degeneration. The agreement has been signed for vascular endothelial growth factor tyrosine kinase inhibitor, tivozanib, to treat ocular diseases. Under the deal, Ophthotech has to pay AVEO Oncology an upfront option fee of USD 500,000 to investigate tivozanib. During the option term, if Ophthotech decides to continue development of the ocular formulation of tivozanib after its initial analysis, AVEO is eligible to receive around USD 8 million in milestone payments based upon the achievement of specified research, development and business goals. Ophthotech now has license to investigate the potential of AVEO's tivozanib, outside of Asia, for the potential treatment of non-oncologic diseases of the eye.

AVEO Pharmaceuticals, Inc. Presents at Brean Capital Life Sciences Summit, Nov-24-2014

AVEO Pharmaceuticals, Inc. Presents at Brean Capital Life Sciences Summit, Nov-24-2014 . Venue: Convene (Formerly Sentry Centers), 730 3rd Avenue, New York, New York, United States.

AVEO Oncology Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

AVEO Oncology reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported collaboration revenue was $873,000 against $323,000 a year ago. Loss from operations was $14,099,000 against $23,608,000 a year ago. Net loss was $14,436,000 or $0.28 basic and diluted net loss per share against $24,306,000 or $0.47 basic and diluted net loss per share a year ago. For the nine-month period, the company reported collaboration revenue was $18,007,000 against $970,000 a year ago. Loss from operations was $37,456,000 against $87,835,000 a year ago. Net loss was $38,845,000 or $0.75 basic and diluted net loss per share against $90,304,000 or $1.78 basic and diluted net loss per share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVEO:US $0.71 USD -0.0005

AVEO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.15 USD -0.01
Bristol-Myers Squibb Co $59.19 USD +1.50
Exelixis Inc $1.36 USD +0.05
GlaxoSmithKline SAE £12.37 EGP 0.00
Takeda Pharmaceutical Co Ltd ¥4,839 JPY +2.50
View Industry Companies
 

Industry Analysis

AVEO

Industry Average

Valuation AVEO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.9x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AVEO PHARMACEUTICALS INC, please visit www.aveopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.